We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register to chat with like-minded investors on our interactive forums.
| Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
|---|---|---|---|---|---|
| Immunodiagnostic Systems Holdings Plc | LSE:IDH | London | Ordinary Share | GB00B01YZ052 | ORD 2P |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| 0.00 | 0.00% | 378.00 | 0.00 | 01:00:00 |
| Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
|---|---|---|---|---|---|
| 0 | 0 | N/A | 0 |
From May 2021 to May 2024
TIDMIDH
RNS Number : 6679E
Immunodiagnostic Systems Hldgs PLC
08 July 2021
Immunodiagnostic Systems Holdings PLC
Exercise of options
08 July 2021
Immunodiagnostic Systems Holdings PLC ("IDS" or the "Company") a specialist producer of manual and automated diagnostic testing kits and instruments for the clinical and research markets, announces that, on 8 July 2021, 169,350 share options were exercised by directors and employees of the Company.
A total of 169,350 new ordinary shares of 2p each in the Company ("Ordinary Shares") have been transferred from treasury stock for the purpose of satisfying the exercise of the share options.
As noted in the announcement on 18 May 2021, these options have been exercised in full shortly prior to the scheme of arrangement to be implemented to effect the recommended cash offer for IDS by PerkinElmer (UK) Holdings Ltd becoming effective.
Total voting rights
Following the above transfer of treasury stock, the Company's issued share capital comprises 29,411,175 Ordinary Shares. Of these 457,728 are held in Treasury. The total voting rights of the Company are 28,953,447 Ordinary Shares and this figure may be used by shareholders in the Company as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change in their interest in, the share capital of the Company under the FCA's Disclosure and Transparency Rules.
The below notifications, made in accordance with Article 19 of the Market Abuse Regulation (EU) 596/2014 as it forms part of domestic law by virtue of the European Union (Withdrawal) Act 2018, gives further detail of the number of options exercised by PDMRs.
For further information:
Hot Features
Premium
Immunodiagnostic Systems Holdings Tel : +44 (0)191
plc 519 0660
Paul Martin, Group Finance
Director
Peel Hunt LLP Tel : +44 (0)207
418 8900
James Steel
Victoria Erskine
Notification and public disclosure of transactions by persons discharging
managerial responsibilities and persons closely associated with them
1. Details of the person discharging managerial responsibilities / person closely associated
a. Name 1. Jaap Stuut
2. Paul Martin
3. Nicola Trewin
4. Soenke Weissenborn
------------------------------ ---------------------------------------------------------------------------------
2. Reason for the notification
-----------------------------------------------------------------------------------------------------------------
a. Position/status 1. Chief Executive Officer
2. Group Finance Director
3. Group HR Director
4. Group Operations Director
------------------------------ ---------------------------------------------------------------------------------
b. Initial notification Initial
/Amendment
------------------------------ ---------------------------------------------------------------------------------
3. Details of the issuer, emission allowance market participant, auction platform, auctioneer
or auction monitor
-----------------------------------------------------------------------------------------------------------------
a. Name Immunodiagnostic Systems Holdings plc
------------------------------ ---------------------------------------------------------------------------------
b. LEI 213800HZMYTD4NGF4L78
------------------------------ ---------------------------------------------------------------------------------
4. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii)
each type of transaction; (iii) each date; and (iv) each place where transactions have been
conducted
-----------------------------------------------------------------------------------------------------------------
a. Description of the Options over ordinary shares of 2p each in Immunodiagnostic Systems Holdings plc
Financial instrument,
type Ordinary shares
of instrument
Identification code
GB00B01YZ052
------------------------------ ---------------------------------------------------------------------------------
b. Nature of the transaction Exercise of Options
------------------------------ ---------------------------------------------------------------------------------
c. Price(s) and volume(s) Employee Number of Options Exercise Price
------------------ ---------------
1. Jaap Stuut 7,500 2.200
----------------------------- ------------------ ---------------
7,500 1.900
----------------------------- ------------------ ---------------
7,500 2.100
------------------ ---------------
7,500 1.950
----------------------------- ------------------ ---------------
2. Paul Martin 30,000 1.320
----------------------------- ------------------ ---------------
6,300 2.900
----------------------------- ------------------ ---------------
15,000 2.200
------------------ ---------------
6,750 1.840
------------------ ---------------
30,000 1.800
------------------ ---------------
9,000 1.700
------------------ ---------------
9,000 2.775
------------------ ---------------
6,300 2.750
------------------ ---------------
6,000 1.950
----------------------------- ------------------ ---------------
3. Nicola Trewin 3,000 2.200
----------------------------- ------------------ ---------------
3,000 1.950
----------------------------- ------------------ ---------------
4. Soenke Weissenborn 6,000 2.490
----------------------------- ------------------ ---------------
6,000 2.270
----------------------------- ------------------ ---------------
------------------------------ ---------------------------------------------------------------------------------
d. Aggregated information Employee Number of Options Weighted Average
* Aggregated volume Exercise Price
Jaap Stuut 30,000 2.038
------------------ -----------------
* Price Nicola Trewin 6,000 2.075
------------------ -----------------
Paul Martin 118,350 1.915
------------------ -----------------
Soenke Weissenborn 12,000 2.380
------------------ -----------------
------------------------------ ---------------------------------------------------------------------------------
e. Date of the transaction 08-July-21
------------------------------ ---------------------------------------------------------------------------------
f. Place of the transaction Outside a trading venue
------------------------------ ---------------------------------------------------------------------------------
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
END
DSHEALXPEENFEFA
(END) Dow Jones Newswires
July 08, 2021 10:13 ET (14:13 GMT)
1 Year Immunodiagnostic Systems Chart |
1 Month Immunodiagnostic Systems Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
